Temazepam (Restoril, Sandoz Pharmaceuticals)
by
McElnay JC, Jones ME, Alexander B.
Drug Intell Clin Pharm 1982 Sep;16(9):650-6


ABSTRACT

Temazepam is a benzodiazepine derivative indicated for the treatment of insomnia. Pharmacokinetic studies of the hard capsule formulation indicate that the mean time to peak is 2.99 hours and the mean elimination half-life is 14.7 hours. Sleep laboratory studies have demonstrated improvements in all sleep parameters except sleep onset latency. Clinically, patients report improvements in all sleep parameters including sleep onset latency. The efficacy of temazepam compares favorably with barbiturates, glutethimide, nitrazepam, lorazepam, oxazepam, and flurazepam. It has not been compared with diazepam in the clinical setting. Side effects include drowsiness, dizziness, and lethargy. The incidence of hangover effects from 15- and 30-mg doses is relatively low. Temazepam has no proven advantages over other benzodiazepine hypnotics. The major issues that need further clarification include temazepam's sleep induction properties and the relative incidence of hangover and rebound insomnia when compared with longer-acting benzodiazepines.
Ligands
Clobazam
Prazepam
Sedatives
Alprazolam
Temazepam
Barbiturates
Benzodiazepines
Temazepam: structure
Clorazepate v lorazepam
Sleep maintenance insomnia
Temazepam and elderly insomniacs
Temazepam (Restoril) and injecting drug users
Diazepam (Valium) and the potato: the natural origin of benzodiazepines


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family